Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series | Zendy

Jessica Atieh | Zendy; Jordan Sack | Zendy; Richard Thomas | Zendy; Osama E. Rahma | Zendy; Michael Camilleri | Zendy; Shilpa Grover | Zendy

AI Assistant Blog Pricing

Open Access

Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series

Author(s) -

Jessica Atieh,

Jordan Sack,

Richard Thomas,

Osama E. Rahma,

Michael Camilleri,

Shilpa Grover

Publication year - 2020

Publication title -

digestive diseases and sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.14

H-Index - 124

eISSN - 1573-2568

pISSN - 0163-2116

DOI - 10.1007/s10620-020-06440-x

Subject(s) - medicine , gastroparesis , ipilimumab , pembrolizumab , nivolumab , cancer , hepatology , gastric emptying , gastroenterology , adverse effect , medical record , stomach , immunotherapy

Immune checkpoint inhibitors (ICI) have improved outcomes in patients with various malignancies; however, they can cause immune-related hepatitis and enterocolitis. Patients on ICI may also develop upper gastrointestinal symptoms and undergo measurement of gastric emptying.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog